Novartis AG (NVS)

93.56
0.70 0.74
NYSE : Health Technology
Prev Close 94.26
Open 94.80
Day Low/High 93.37 / 94.87
52 Wk Low/High 74.97 / 96.31
Volume 3.48M
Avg Volume 2.21M
Exchange NYSE
Shares Outstanding 2.55B
Market Cap 236.72B
EPS 5.50
P/E Ratio 17.52
Div & Yield 1.84 (2.04%)
Novartis Doesn't Appear Ready to Make Healthy Move Higher

Novartis Doesn't Appear Ready to Make Healthy Move Higher

The drugmaker may have made a low, but the charts indicate we are a long way from a bottom.

Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning

Deutsche Bank Fails Stress Test and 4 Other Stories to Watch Friday Morning

Happy Friday! These are the stories you must know ahead of the opening bell.

Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either

Starbucks Leaves a Bitter Taste and Doesn't Suit My Investment Palate Either

For my portfolio, you can't beat this SBUX competitor -- and for a cup of coffee.

3 Potential Biotech Buyout Targets in the Second Quarter

3 Potential Biotech Buyout Targets in the Second Quarter

Novartis' deal for AveXis has ignited a rally in other gene-therapy concerns.

Getting Ready for Biotech Earnings

Getting Ready for Biotech Earnings

Now that M&A is picking up in the sector, here's what to watch as earnings releases begin to hit.

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Video: Jim Cramer Reacts to Novartis' Acquisition of AveXis

Novartis agreed to acquire AveXis for $8.7 billion on Monday. TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer reacts.

Possible Biotech Takeout Plays

Possible Biotech Takeout Plays

A look at possible second-quarter M&A activity in the biotech sector.

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Stock Market's Overhead Resistance Is Now More Powerful Than V-Shaped Bounces

Two failed bounces this year have made it tougher for stocks to build strong sustained momentum.

5 Thing You Must Know Before Monday's Opening Bell

5 Thing You Must Know Before Monday's Opening Bell

U.S. stock futures rise Monday following indications that Donald Trump was softening his approach toward China; Deutsche Bank ousts CEO John Cryan; Novartis buys AveXis; Facebook to notify users whose data may have been shared with Cambridge Analytica.

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

Novartis to Exit its Consumer Business and 4 Other Stories You Must Know Tuesday

With Wall Street responding to one of the strongest rallies in years, here's what you need to know premarket Tuesday.

There Is Good and a Lot of Bad in General Electric Earnings

There Is Good and a Lot of Bad in General Electric Earnings

John Flannery sees progress being made on GE's initiatives, but that is what I expected him to say.

Markets Nicely Off Today's Lows

Markets are down across the board in the first hour of trading. However, we are nicely off the lows of the day. Financials are bucking the early downward tilt of the market and are up today. This sector continues to benefit from slowly rising intere...

What Does CVS's Aetna Acquisition Mean for Amazon?

What Does CVS's Aetna Acquisition Mean for Amazon?

Is CVS's planned acquisition of Aetna just a reaction to Amazon's dive into healthcare? Here's what we know so far.

How to Manage GE Risk and the Netflix-Disney Fight: Market Recon

How to Manage GE Risk and the Netflix-Disney Fight: Market Recon

Entering GE too early has its costs, but there are ways to mitigate them.

Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday

Amazon, Novartis and Netflix - This is What You Need to Know on Tuesday

European markets opened flat as investors await the European Central Bank meeting

European Stocks Euphoria Is Running High ... Maybe Too High

European Stocks Euphoria Is Running High ... Maybe Too High

European stock markets are priced almost to perfection ahead of an earnings deluge.

Why I'm Positive on Novartis

Why I'm Positive on Novartis

Here's where to buy NVS.

Surveying the NASH Drug Landscape

Surveying the NASH Drug Landscape

Biotech investors should keep a close eye on the progress in this huge potential market.

Drugmakers Suffer After Trump Tweet

Drugmakers Suffer After Trump Tweet

Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.

Cramer: Money's Being Thrown at Almost Everything in the Market

Cramer: Money's Being Thrown at Almost Everything in the Market

There are nearly too many surging sectors to count.

Novartis Shows the World a Take of 2 Charts

Novartis Shows the World a Take of 2 Charts

Novartis has seen some very aggressive buying the past five months -- time to join in.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Wake Up Wall Street: Positive Earnings Drive Early Trading Higher

Reports from DuPont and Alibaba looked promising for the markets on Wednesday.

News Out of Europe: Intesa Confirms Potential Bid for Generali

News Out of Europe: Intesa Confirms Potential Bid for Generali

News of Intesa's potential takeover bid extended Generali's three-day gains to 15%.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Prepare for Biotech Action Aplenty Today

As we await the jobs report, there is significant news across the biotech sector in the past 24 hours on some names I have mentioned in these pages. Amgen should be up nicely today after a judge stated that Regeneron would have to pull its PCKS9 inh...

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

Ophthtech Shares Plunge as Drug Fails in Late Stage Trial

A drug made by Ophthotech failed in a late stage trial, sending shares of the stock plunging.